With US Food and Drug Administration approval for Bristol Myers Squibb Company’s Reblozyl (luspatercept) as a first-line treatment for anemia in patients with very low- to intermediate-risk myelodysplastic syndromes (MDS), EVP and chief commercialization officer Adam Lenkowsky noted in an interview with Scrip, the company’s forecast of $4bn-plus in non-risk-adjusted sales for the erythroid maturation agent by 2029 is largely de-risked, now that the product is cleared in its biggest market to date.
BMS Broadens Market, De-Risks Long-Term Revenue Potential For Reblozyl
FDA Approves Drug’s Third US Indication And Its Biggest Yet
As a first-line treatment for anemia in patients with myelodysplastic syndromes, Reblozyl is approved for indications that will account for 75%-80% of the $4bn-plus in sales Bristol has forecast by 2029.
More from New Products
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.
More from Scrip
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.